Gloria Salvo1, Pedro T Ramirez2, Mario M Leitao3, David Cibula4, Xiaohua Wu5, Henrik Falconer6, Jan Persson7, Myriam Perrotta8, Berit J Mosgaard9, Ali Kucukmetin10, Igor Berlev11, Gabriel Rendon12, Kaijiang Liu13, Marcelo Vieira14, Mihai E Capilna15, Christina Fotopoulou16, Glauco Baiocchi17, Dilyara Kaidarova18, Reitan Ribeiro19, Silvana Pedra-Nobre3, Roman Kocian4, Xiaoqi Li5, Jin Li5, Kolbrún Pálsdóttir6, Florencia Noll8, Stuart Rundle10, Elena Ulrikh20, Zhijun Hu13, Mihai Gheorghe15, Srdjan Saso16, Raikhan Bolatbekova18, Audrey Tsunoda21, Brandelyn Pitcher22, Jimin Wu22, Diana Urbauer22, Rene Pareja23. 1. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: GSalvo@mdandeson.org. 2. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. 3. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. 4. Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic. 5. Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. 6. Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden. 7. Department of Obstetrics and Gynecology, Skåne University Hospital, Lund, Sweden; Department of Clinical Sciences, Faculty of Medicine, Lund University Lund, Sweden. 8. Servicio de Ginecología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. 9. Department of Gynecology, University Hospital Copenhagen, Rigshospitalet, Copenhagen, Denmark. 10. Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital, Gateshead, United Kingdom. 11. Department of Gynecologic Oncology, N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia. 12. Department of Gynecologic Oncology, Instituto de Cancerología Las Américas Auna, Medellín, Colombia. 13. Department of Gynecologic Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. 14. Department of Gynecologic Oncology, Hospital Israelita Albert Einstein, São Paulo, Brazil; Department of Gynecologic Oncology, Barretos Cancer Hospital, Barretos, Brazil. 15. First Obstetrics and Gynecology Clinic, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Târgu Mureş, Târgu Mureş, Romania. 16. Department of Surgery and Cancer, Imperial College London and West London Gynaecological Cancer Centre, Imperial College NHS Trust, London, United Kingdom. 17. Department of Gynecologic Oncology, AC Camargo Cancer Center, São Paulo, Brazil. 18. Department of Gynecologic Oncology, Kazakh Institute of Oncology and Radiology, Almaty, Kazakhstan. 19. Department of Gynecologic Oncology, Hospital Erasto Gaertner, Curitiba, Brazil. 20. Almazov National Medical Research Centre, North-Western State Medical University named after I. I. Mechnikov, Saint Petersburg, Russia. 21. Department of Gynecologic Oncology, Hospital Israelita Albert Einstein, São Paulo, Brazil; Department of Gynecologic Oncology, Hospital Erasto Gaertner, Curitiba, Brazil; Department of Gynecologic Oncology, Pilar Hospital, Curitiba, Brazil. 22. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX. 23. Department of Gynecologic Oncology, Astorga Clínica de Oncología, Medellín, Colombia; Instituto Nacional de Cancerología, Bogotá, Colombia.
Abstract
BACKGROUND: Minimally invasive radical trachelectomy has emerged as an alternative to open radical hysterectomy for patients with early-stage cervical cancer desiring future fertility. Recent data suggest worse oncologic outcomes after minimally invasive radical hysterectomy than after open radical hysterectomy in stage I cervical cancer. OBJECTIVE: We aimed to compare 4.5-year disease-free survival after open vs minimally invasive radical trachelectomy. STUDY DESIGN: This was a collaborative, international retrospective study (International Radical Trachelectomy Assessment Study) of patients treated during 2005-2017 at 18 centers in 12 countries. Eligible patients had squamous carcinoma, adenocarcinoma, or adenosquamous carcinoma; had a preoperative tumor size of ≤2 cm; and underwent open or minimally invasive (robotic or laparoscopic) radical trachelectomy with nodal assessment (pelvic lymphadenectomy and/or sentinel lymph node biopsy). The exclusion criteria included neoadjuvant chemotherapy or preoperative pelvic radiotherapy, previous lymphadenectomy or pelvic retroperitoneal surgery, pregnancy, stage IA1 disease with lymphovascular space invasion, aborted trachelectomy (conversion to radical hysterectomy), or vaginal approach. Surgical approach, indication, and adjuvant therapy regimen were at the discretion of the treating institution. A total of 715 patients were entered into the study database. However, 69 patients were excluded, leaving 646 in the analysis. Endpoints were the 4.5-year disease-free survival rate (primary), 4.5-year overall survival rate (secondary), and recurrence rate (secondary). Kaplan-Meier methods were used to estimate disease-free survival and overall survival. A post hoc weighted analysis was performed, comparing the recurrence rates between surgical approaches, with open surgery being considered as standard and minimally invasive surgery as experimental. RESULTS: Of 646 patients, 358 underwent open surgery, and 288 underwent minimally invasive surgery. The median (range) patient age was 32 (20-42) years for open surgery vs 31 (18-45) years for minimally invasive surgery (P=.11). Median (range) pathologic tumor size was 15 (0-31) mm for open surgery and 12 (0.8-40) mm for minimally invasive surgery (P=.33). The rates of pelvic nodal involvement were 5.3% (19 of 358 patients) for open surgery and 4.9% (14 of 288 patients) for minimally invasive surgery (P=.81). Median (range) follow-up time was 5.5 (0.20-16.70) years for open surgery and 3.1 years (0.02-11.10) years for minimally invasive surgery (P<.001). At 4.5 years, 17 of 358 patients (4.7%) with open surgery and 18 of 288 patients (6.2%) with minimally invasive surgery had recurrence (P=.40). The 4.5-year disease-free survival rates were 94.3% (95% confidence interval, 91.6-97.0) for open surgery and 91.5% (95% confidence interval, 87.6-95.6) for minimally invasive surgery (log-rank P=.37). Post hoc propensity score analysis of recurrence risk showed no difference between surgical approaches (P=.42). At 4.5 years, there were 6 disease-related deaths (open surgery, 3; minimally invasive surgery, 3) (log-rank P=.49). The 4.5-year overall survival rates were 99.2% (95% confidence interval, 97.6-99.7) for open surgery and 99.0% (95% confidence interval, 79.0-99.8) for minimally invasive surgery. CONCLUSION: The 4.5-year disease-free survival rates did not differ between open radical trachelectomy and minimally invasive radical trachelectomy. However, recurrence rates in each group were low. Ongoing prospective studies of conservative management of early-stage cervical cancer may help guide future management.
BACKGROUND: Minimally invasive radical trachelectomy has emerged as an alternative to open radical hysterectomy for patients with early-stage cervical cancer desiring future fertility. Recent data suggest worse oncologic outcomes after minimally invasive radical hysterectomy than after open radical hysterectomy in stage I cervical cancer. OBJECTIVE: We aimed to compare 4.5-year disease-free survival after open vs minimally invasive radical trachelectomy. STUDY DESIGN: This was a collaborative, international retrospective study (International Radical Trachelectomy Assessment Study) of patients treated during 2005-2017 at 18 centers in 12 countries. Eligible patients had squamous carcinoma, adenocarcinoma, or adenosquamous carcinoma; had a preoperative tumor size of ≤2 cm; and underwent open or minimally invasive (robotic or laparoscopic) radical trachelectomy with nodal assessment (pelvic lymphadenectomy and/or sentinel lymph node biopsy). The exclusion criteria included neoadjuvant chemotherapy or preoperative pelvic radiotherapy, previous lymphadenectomy or pelvic retroperitoneal surgery, pregnancy, stage IA1 disease with lymphovascular space invasion, aborted trachelectomy (conversion to radical hysterectomy), or vaginal approach. Surgical approach, indication, and adjuvant therapy regimen were at the discretion of the treating institution. A total of 715 patients were entered into the study database. However, 69 patients were excluded, leaving 646 in the analysis. Endpoints were the 4.5-year disease-free survival rate (primary), 4.5-year overall survival rate (secondary), and recurrence rate (secondary). Kaplan-Meier methods were used to estimate disease-free survival and overall survival. A post hoc weighted analysis was performed, comparing the recurrence rates between surgical approaches, with open surgery being considered as standard and minimally invasive surgery as experimental. RESULTS: Of 646 patients, 358 underwent open surgery, and 288 underwent minimally invasive surgery. The median (range) patient age was 32 (20-42) years for open surgery vs 31 (18-45) years for minimally invasive surgery (P=.11). Median (range) pathologic tumor size was 15 (0-31) mm for open surgery and 12 (0.8-40) mm for minimally invasive surgery (P=.33). The rates of pelvic nodal involvement were 5.3% (19 of 358 patients) for open surgery and 4.9% (14 of 288 patients) for minimally invasive surgery (P=.81). Median (range) follow-up time was 5.5 (0.20-16.70) years for open surgery and 3.1 years (0.02-11.10) years for minimally invasive surgery (P<.001). At 4.5 years, 17 of 358 patients (4.7%) with open surgery and 18 of 288 patients (6.2%) with minimally invasive surgery had recurrence (P=.40). The 4.5-year disease-free survival rates were 94.3% (95% confidence interval, 91.6-97.0) for open surgery and 91.5% (95% confidence interval, 87.6-95.6) for minimally invasive surgery (log-rank P=.37). Post hoc propensity score analysis of recurrence risk showed no difference between surgical approaches (P=.42). At 4.5 years, there were 6 disease-related deaths (open surgery, 3; minimally invasive surgery, 3) (log-rank P=.49). The 4.5-year overall survival rates were 99.2% (95% confidence interval, 97.6-99.7) for open surgery and 99.0% (95% confidence interval, 79.0-99.8) for minimally invasive surgery. CONCLUSION: The 4.5-year disease-free survival rates did not differ between open radical trachelectomy and minimally invasive radical trachelectomy. However, recurrence rates in each group were low. Ongoing prospective studies of conservative management of early-stage cervical cancer may help guide future management.
Authors: Roni Nitecki; Pedro T Ramirez; Michael Frumovitz; Kate J Krause; Ana I Tergas; Jason D Wright; J Alejandro Rauh-Hain; Alexander Melamed Journal: JAMA Oncol Date: 2020-07-01 Impact factor: 31.777
Authors: Koji Matsuo; Ling Chen; Rachel S Mandelbaum; Alexander Melamed; Lynda D Roman; Jason D Wright Journal: Am J Obstet Gynecol Date: 2019-02-22 Impact factor: 8.661
Authors: Koji Matsuo; Shinya Matsuzaki; Rachel S Mandelbaum; Kazuhide Matsushima; Maximilian Klar; Brendan H Grubbs; Lynda D Roman; Jason D Wright Journal: Gynecol Oncol Date: 2020-01-22 Impact factor: 5.482
Authors: Gloria Salvo; Pedro T Ramirez; Mario Leitao; David Cibula; Christina Fotopoulou; Ali Kucukmetin; Gabriel Rendon; Myriam Perrotta; Reitan Ribeiro; Marcelo Vieira; Glauco Baiocchi; Henrik Falconer; Jan Persson; Xiaohua Wu; Mihai Emil Căpilna; Nicolae Ioanid; Berit Jul Mosgaard; Igor Berlev; Dilyara Kaidarova; Alexander Babatunde Olawaiye; Kaijiang Liu; Silvana Pedra Nobre; Roman Kocian; Srdjan Saso; Stuart Rundle; Florencia Noll; Audrey Tieko Tsunoda; Kolbrun Palsdottir; Xiaoqi Li; Elena Ulrikh; Zhijun Hu; Rene Pareja Journal: Int J Gynecol Cancer Date: 2019-02-13 Impact factor: 3.437
Authors: Shitanshu Uppal; Paola A Gehrig; Katherine Peng; Kristin L Bixel; Koji Matsuo; Monica H Vetter; Brittany A Davidson; M Paige Cisa; Brittany F Lees; Laurie L Brunette; Katherine Tucker; Allison Stuart Staley; Walter H Gotlieb; Robert W Holloway; Kathleen G Essel; Laura L Holman; Ester Goldfeld; Alexander Olawaiye; Stephen L Rose Journal: J Clin Oncol Date: 2020-02-07 Impact factor: 44.544
Authors: Alexander Melamed; Daniel J Margul; Ling Chen; Nancy L Keating; Marcela G Del Carmen; Junhua Yang; Brandon-Luke L Seagle; Amy Alexander; Emma L Barber; Laurel W Rice; Jason D Wright; Masha Kocherginsky; Shohreh Shahabi; J Alejandro Rauh-Hain Journal: N Engl J Med Date: 2018-10-31 Impact factor: 91.245
Authors: Pedro T Ramirez; Michael Frumovitz; Rene Pareja; Aldo Lopez; Marcelo Vieira; Reitan Ribeiro; Alessandro Buda; Xiaojian Yan; Yao Shuzhong; Naven Chetty; David Isla; Mariano Tamura; Tao Zhu; Kristy P Robledo; Val Gebski; Rebecca Asher; Vanessa Behan; James L Nicklin; Robert L Coleman; Andreas Obermair Journal: N Engl J Med Date: 2018-10-31 Impact factor: 91.245
Authors: Evan S Smith; Ashley S Moon; Robin O'Hanlon; Mario M Leitao; Yukio Sonoda; Nadeem R Abu-Rustum; Jennifer J Mueller Journal: Obstet Gynecol Date: 2020-09 Impact factor: 7.623
Authors: Antoni Llueca; Maria Victoria Ibañez; Aureli Torne; Antonio Gil-Moreno; Angel Martin-Jimenez; Berta Diaz-Feijoo; Anna Serra; Maria Teresa Climent; Blanca Gil-Ibañez Journal: J Pers Med Date: 2022-06-30